Lee, G., Ryu, M., Lee, J., Oh, S., Kim, E., Lee, J., . . . Kang, Y. (2003). The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. Korean Academy of Medical Sciences.
Chicago Style CitationLee, Gyeong-Won, et al. The Prophylactic Use of Lamivudine Can Maintain Dose-intensity of Adriamycin in Hepatitis-B Surface Antigen (HBs Ag)-positive Patients With Non-Hodgkin's Lymphoma Who Receive Cytotoxic Chemotherapy. Korean Academy of Medical Sciences, 2003.
MLA CitationLee, Gyeong-Won, et al. The Prophylactic Use of Lamivudine Can Maintain Dose-intensity of Adriamycin in Hepatitis-B Surface Antigen (HBs Ag)-positive Patients With Non-Hodgkin's Lymphoma Who Receive Cytotoxic Chemotherapy. Korean Academy of Medical Sciences, 2003.